Intensified polarization for R&D among listed pharmas
R&D polarization is being intensified among listed pharmaceutical companies.
While there is a company investing more than 20% of their sales, a number of companies are still spending less than 1% of their sales into R&D.
Yakup Shinmoon(www.yakup.com) analyzed KOSPI and KOSDAQ listed pharmaceuti...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
